Analysts expect DexCom, Inc. (NASDAQ:DXCM) to post earnings of $0.03 per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for DexCom’s earnings, with estimates ranging from ($0.10) to $0.13. DexCom posted earnings per share of ($0.09) during the same quarter last year, which indicates a positive year over year growth rate of 133.3%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that DexCom will report full-year earnings of ($0.61) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.41). For the next fiscal year, analysts forecast that the business will post earnings of ($0.39) per share, with EPS estimates ranging from ($0.69) to $0.06. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that cover DexCom.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.11. DexCom had a negative net margin of 7.21% and a negative return on equity of 20.44%.
DexCom (NASDAQ:DXCM) traded down $0.09 during midday trading on Friday, hitting $56.32. 1,263,170 shares of the stock were exchanged, compared to its average volume of 2,120,818. DexCom has a 52 week low of $42.62 and a 52 week high of $86.32. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50. The company has a market cap of $4,860.00, a P/E ratio of -98.81 and a beta of 0.31.
In other news, Director Steven R. Altman acquired 10,000 shares of the stock in a transaction dated Monday, November 6th. The stock was purchased at an average cost of $49.61 per share, with a total value of $496,100.00. Following the completion of the purchase, the director now owns 4,353 shares in the company, valued at approximately $215,952.33. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 12,000 shares of the company’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $55.00, for a total transaction of $660,000.00. The disclosure for this sale can be found here. Insiders sold 38,140 shares of company stock valued at $2,158,576 over the last three months. 1.70% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of DXCM. Schwab Charles Investment Management Inc. raised its stake in shares of DexCom by 13.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 256,848 shares of the medical device company’s stock valued at $18,789,000 after acquiring an additional 29,608 shares during the last quarter. Comerica Bank raised its stake in shares of DexCom by 8.7% during the second quarter. Comerica Bank now owns 17,586 shares of the medical device company’s stock valued at $1,225,000 after acquiring an additional 1,403 shares during the last quarter. Tredje AP fonden bought a new position in shares of DexCom during the second quarter valued at about $331,000. Stephens Inc. AR raised its stake in shares of DexCom by 78.8% during the second quarter. Stephens Inc. AR now owns 7,135 shares of the medical device company’s stock valued at $522,000 after acquiring an additional 3,145 shares during the last quarter. Finally, TIAA CREF Investment Management LLC raised its stake in shares of DexCom by 8.2% during the second quarter. TIAA CREF Investment Management LLC now owns 310,870 shares of the medical device company’s stock valued at $22,740,000 after acquiring an additional 23,540 shares during the last quarter.
COPYRIGHT VIOLATION WARNING: “” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.chaffeybreeze.com/2018/01/17/1323044.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.